A randomised phase II study of inhaled xenon for neuroprotection in out-of-hospital cardiac arrest (OHCA) patients

Trial Profile

A randomised phase II study of inhaled xenon for neuroprotection in out-of-hospital cardiac arrest (OHCA) patients

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Xenon (Primary) ; Oxygen
  • Indications Chronic brain damage
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2017 Primary endpoint has been met. (Reduction of white matter brain damage, assessed by Magnetic Resonance Imaging (MRI)), according to a Mallinckrodt plc media release.
    • 02 Oct 2017 Results published in a Mallinckrodt plc media release.
    • 11 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top